Literature DB >> 28371398

Targeting Tankyrase to Fight WNT-dependent Tumours.

Tor Espen Thorvaldsen1,2.   

Abstract

Aberrant WNT signalling activity is linked to various diseases due to the WNT dependency of fundamental processes during development and in adult tissue homeostasis. Mutations in components of the multi-protein β-catenin destruction complex promote excessive amounts of the main transcriptional activator β-catenin and are particularly common in colorectal cancer (CRC). The tankyrase enzymes were recently implicated as negative regulators of destruction complex activity by mediating degradation of the scaffolding protein AXIN. Indeed, tankyrase inhibitors (TNKSi) have emerged as promising therapeutics by restoring functional signal-limiting destruction complexes in CRCs. Furthermore, as TNKSi-induced destruction complexes (so-called degradasomes) can be visualized by microscopy, they have served as a valuable experimental model system to address unresolved aspects regarding the structure, function and composition of the β-catenin destruction complex. This MiniReview provides an overview of the current knowledge on the regulatory mechanisms and interactions that govern the β-catenin destruction complex activity. It further highlights the potential of TNKSi as anticancer drugs and as a novel research tool to dissect the WNT signalling pathway.
© 2017 Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society).

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28371398     DOI: 10.1111/bcpt.12786

Source DB:  PubMed          Journal:  Basic Clin Pharmacol Toxicol        ISSN: 1742-7835            Impact factor:   4.080


  7 in total

1.  Novel 4-Heteroarylcarbonyl-N-(phenyl or heteroaryl) Piperidine-1-carboxamides as Tankyrase Inhibitors.

Authors:  Ram W Sabnis
Journal:  ACS Med Chem Lett       Date:  2020-08-19       Impact factor: 4.345

2.  Tankyrase modulates insulin sensitivity in skeletal muscle cells by regulating the stability of GLUT4 vesicle proteins.

Authors:  Zhiduan Su; Vinita Deshpande; David E James; Jacqueline Stöckli
Journal:  J Biol Chem       Date:  2018-04-18       Impact factor: 5.157

3.  Tankyrase inhibitors suppress hepatocellular carcinoma cell growth via modulating the Hippo cascade.

Authors:  Jiaoyuan Jia; Yu Qiao; Maria G Pilo; Antonio Cigliano; Xianqiong Liu; Zixuan Shao; Diego F Calvisi; Xin Chen
Journal:  PLoS One       Date:  2017-09-06       Impact factor: 3.240

4.  A FRET-based high-throughput screening platform for the discovery of chemical probes targeting the scaffolding functions of human tankyrases.

Authors:  Sven T Sowa; Carlos Vela-Rodríguez; Albert Galera-Prat; Mariana Cázares-Olivera; Renata Prunskaite-Hyyryläinen; Alexander Ignatev; Lari Lehtiö
Journal:  Sci Rep       Date:  2020-07-23       Impact factor: 4.379

5.  Evaluation of AXIN1 and AXIN2 as targets of tankyrase inhibition in hepatocellular carcinoma cell lines.

Authors:  Wenhui Wang; Pengyu Liu; Marla Lavrijsen; Shan Li; Ruyi Zhang; Shanshan Li; Wesley S van de Geer; Harmen J G van de Werken; Maikel P Peppelenbosch; Ron Smits
Journal:  Sci Rep       Date:  2021-04-02       Impact factor: 4.379

6.  The zinc-binding motif in tankyrases is required for the structural integrity of the catalytic ADP-ribosyltransferase domain.

Authors:  Sven T Sowa; Lari Lehtiö
Journal:  Open Biol       Date:  2022-03-23       Impact factor: 6.411

7.  Discovery of Novel Inhibitor for WNT/β-Catenin Pathway by Tankyrase 1/2 Structure-Based Virtual Screening.

Authors:  Bo Li; Jinxia Liang; Feng Lu; Guandi Zeng; Jindao Zhang; Yinxing Ma; Peng Liu; Qin Wang; Qian Zhou; Liang Chen
Journal:  Molecules       Date:  2020-04-06       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.